When to Perform a Pregnancy Test with Depo-Provera
A pregnancy test should be performed before each Depo-Provera injection if it is reasonably certain the patient is not pregnant based on clinical criteria, and a follow-up pregnancy test should be done 2-4 weeks after starting if there was any uncertainty at initiation.
Before Starting Depo-Provera
The most critical time for pregnancy testing is before the first injection. According to CDC guidelines, DMPA can be initiated at any time if the provider is "reasonably certain" the patient is not pregnant 1. The provider can be reasonably certain if the patient meets specific criteria 1:
- Less than 7 days since menstrual bleeding started (no backup contraception needed)
- 21+ days postpartum, amenorrheic, and fully/nearly fully breastfeeding (≥85% of feeds)
- Within 7 days post-abortion
- No intercourse since last menses
- Correctly using another reliable contraceptive method
If DMPA is started more than 7 days after menses began, backup contraception (condoms or abstinence) is required for 7 consecutive days 2, 1.
When Uncertainty Exists
If there is uncertainty about pregnancy status at the time of desired DMPA initiation, the benefits of starting likely exceed any risk 3. In this scenario:
- Administer the injection
- Schedule a follow-up pregnancy test in 2-4 weeks 3
- Counsel the patient about this approach
This recommendation reflects the 2024 CDC guidance recognizing that delaying contraception poses greater risks than potential early pregnancy exposure to DMPA.
Before Repeat Injections
For ongoing DMPA use, pregnancy testing should be considered:
- If the patient is more than 2 weeks late (≥15 weeks from last injection) 4, 1
- If there are symptoms suggesting pregnancy (though amenorrhea is common and expected with DMPA use)
- If the patient had unprotected intercourse during a late injection window
The grace period for repeat injections is up to 2 weeks late (15 weeks total from last injection) without requiring additional contraceptive protection 1. If presenting at 15+ weeks from the last injection, perform a pregnancy test before administering the next dose, as contraceptive effectiveness cannot be assured beyond this window.
Special Circumstances
Undiagnosed vaginal bleeding: This is a contraindication to DMPA use per FDA labeling 5. Rule out pregnancy and other pathology before initiating or continuing DMPA 5.
Postpartum timing: DMPA can be started immediately postpartum (category 1 for non-breastfeeding, category 2 if <1 month postpartum and breastfeeding) 4. Pregnancy testing is generally not needed in the immediate postpartum period if timing is appropriate.
Common Pitfalls
- Don't delay contraception unnecessarily: Waiting for menses when pregnancy can be reasonably excluded increases unintended pregnancy risk
- Don't confuse DMPA-induced amenorrhea with pregnancy: By 12 months of use, 57% of women experience amenorrhea 2. This is expected and does not require routine pregnancy testing unless other concerning features are present
- Don't forget the 7-day backup rule: When starting DMPA >7 days after menses, backup contraception is essential 2, 1
The evidence shows pregnancy during DMPA use is rare (0.42 per 1000 women-years) 6, but when it occurs, it's often unrecognized until after the first trimester because of expected amenorrhea. While fetal exposure to MPA has not been shown to cause measurable teratogenic risk 7, pregnancy is listed as a contraindication in FDA labeling 5.